Analysts expect Prothena Corp to report an earnings per share (EPS) of $-1.03. The announcement from Prothena Corp is eagerly ...

After a long career as an accomplished TV and radio journalist for programs like AM, This Day Tonight and Beyond 2000, Iain ...

The journalist’s organs had been severely damaged by the disease, which causes a buildup of amyloid proteins in the body.

The European Medicines Agency has recommended marketing approval for Alyftrek for cystic fibrosis and Attrogy for a form of hereditary amyloidosis.

A new FDA-approved ATTR-CM treatment is giving new hope to patients — especially older Black Americans who are at high risk ...

Fortress Biotech, Inc.’s FBIO share price has dipped by 6.18%, which has investors questioning if this is right time to buy.

CRISPR Therapeutics and Intellia face 2025 volatility, but CRSP’s strong cash and launches make it more attractive than NTLA.

Hailing from Abyssinia, which is now known as Ethiopia, this regal-looking breed is believed to have been imported into the ...

Alnylam Pharmaceuticals’ RNAi therapeutic vutrisiran has been recommended by the European Medicines Agency’s human medicines ...

Prothena today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025.

Learn more about whether Alnylam Pharmaceuticals, Inc. or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.